Cognito Therapeutics has reported new clinical data reinforcing the effectiveness of its non-invasive Spectris neuromodulation system in treating Alzheimer’s disease. Presented at the Alzheimer’s Association International Conference 2025, the findings highlight improvements in cognition, daily function, and brain structure.
Spectris delivers synchronized light and sound at 40 Hz to stimulate gamma brain waves, disrupted in Alzheimer’s. In the OVERTURE trial and its open-label extension, patients experienced significant delays in cognitive and structural decline — including up to 9.9 months of “time saved” across key clinical endpoints.
MRI analyses showed preservation of white matter and myelin integrity. Patient-reported outcomes also improved, with less decline in areas like independence, communication, and emotional stability. Daily adherence to therapy exceeded 85%.
Cognito aims to establish Spectris as a safe, effective neuromodulation therapy that shifts the Alzheimer’s treatment paradigm.
Follow MEDWIRE.AI for the latest in digital neuromodulation therapies.
